Medicaid Formulary | January 2021 · 2021. 1. 6. · 5 Dosage forms on the document will be consistent with the category and use where listed. nystatin The above nystatin entry listed

2021FORMULARY

SERVING MEDICAID, CHILD HEALTH PLUS, PARTNERSHIP IN CARE (SNP) & ENHANCED (HARP) PLAN

1

MetroPlus Health Plan (12/30/2020) INTRODUCTION ...................................................................................................................................................................................................... 4 PREFACE ................................................................................................................................................................................................................. 4 DRUG LIST PRODUCT DESCRIPTIONS ................................................................................................................................................................ 4 GENERIC SUBSTITUTION ...................................................................................................................................................................................... 5 NON-COVERED MEDICATIONS ............................................................................................................................................................................. 5 OVER-THE-COUNTER DRUG COVERAGE ........................................................................................................................................................... 5 SPECIALTY PLAN DESIGN .................................................................................................................................................................................... 5 PLAN DESIGN.......................................................................................................................................................................................................... 6 LEGEND ................................................................................................................................................................................................................... 6 NOTICE ..................................................................................................................................................................................................................... 6 ANALGESICS........................................................................................................................................................................................................... 7

NSAIDs ........................................................................................................................................................................................................... 7 COX-2 INHIBITORS ....................................................................................................................................................................................... 7 GOUT ............................................................................................................................................................................................................. 7 OPIOID ANALGESICS ................................................................................................................................................................................... 7 NON-OPIOID ANALGESICS .......................................................................................................................................................................... 8

ANTI-INFECTIVES ................................................................................................................................................................................................... 8 ANTIBACTERIALS ......................................................................................................................................................................................... 8 ANTIFUNGALS .............................................................................................................................................................................................. 9 ANTIMALARIALS ........................................................................................................................................................................................... 9 ANTIRETROVIRAL AGENTS ........................................................................................................................................................................ 9 ANTITUBERCULAR AGENTS ..................................................................................................................................................................... 10 ANTIVIRALS................................................................................................................................................................................................. 10 MISCELLANEOUS ....................................................................................................................................................................................... 11

ANTINEOPLASTIC AGENTS ................................................................................................................................................................................ 11 ALKYLATING AGENTS ............................................................................................................................................................................... 11 ANTIMETABOLITES .................................................................................................................................................................................... 11 HORMONAL ANTINEOPLASTIC AGENTS ................................................................................................................................................. 12 IMMUNOMODULATORS ............................................................................................................................................................................. 12 KINASE INHIBITORS ................................................................................................................................................................................... 12 MISCELLANEOUS ....................................................................................................................................................................................... 13

CARDIOVASCULAR .............................................................................................................................................................................................. 13 ACE INHIBITORS ........................................................................................................................................................................................ 13 ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS ........................................................................................................ 13 ACE INHIBITOR/DIURETIC COMBINATIONS ............................................................................................................................................ 13 ADRENOLYTICS, CENTRAL ....................................................................................................................................................................... 13 ALDOSTERONE RECEPTOR ANTAGONISTS .......................................................................................................................................... 14 ALPHA BLOCKERS ..................................................................................................................................................................................... 14 ANGIOTENSIN II RECEPTOR ANTAGONISTS/DIURETIC COMBINATIONS ........................................................................................... 14 ANTIARRHYTHMICS ................................................................................................................................................................................... 14 ANTILIPEMICS............................................................................................................................................................................................. 14 BETA-BLOCKERS ....................................................................................................................................................................................... 15 BETA-BLOCKER/DIURETIC COMBINATIONS ........................................................................................................................................... 15 CALCIUM CHANNEL BLOCKERS .............................................................................................................................................................. 15 DIGITALIS GLYCOSIDES ............................................................................................................................................................................ 16 DIURETICS .................................................................................................................................................................................................. 16 HEART FAILURE ......................................................................................................................................................................................... 16 NITRATES .................................................................................................................................................................................................... 16 PULMONARY ARTERIAL HYPERTENSION .............................................................................................................................................. 16 MISCELLANEOUS ....................................................................................................................................................................................... 17

CENTRAL NERVOUS SYSTEM ............................................................................................................................................................................ 17 ANTIANXIETY .............................................................................................................................................................................................. 17

2

ANTICONVULSANTS .................................................................................................................................................................................. 17 ANTIDEMENTIA ........................................................................................................................................................................................... 18 ANTIDEPRESSANTS .................................................................................................................................................................................. 18 ANTIPARKINSONIAN AGENTS .................................................................................................................................................................. 19 ANTIPSYCHOTICS ...................................................................................................................................................................................... 19 ATTENTION DEFICIT HYPERACTIVITY DISORDER ................................................................................................................................ 20 FIBROMYALGIA .......................................................................................................................................................................................... 20 HYPNOTICS ................................................................................................................................................................................................. 20 MIGRAINE .................................................................................................................................................................................................... 20 MOOD STABILIZERS .................................................................................................................................................................................. 20 MULTIPLE SCLEROSIS AGENTS .............................................................................................................................................................. 20 MUSCULOSKELETAL THERAPY AGENTS ............................................................................................................................................... 21 MYASTHENIA GRAVIS ............................................................................................................................................................................... 21 NARCOLEPSY ............................................................................................................................................................................................. 21 PSYCHOTHERAPEUTIC-MISCELLANEOUS ............................................................................................................................................. 21

ENDOCRINE AND METABOLIC ........................................................................................................................................................................... 21 ANDROGENS .............................................................................................................................................................................................. 21 ANTIDIABETICS .......................................................................................................................................................................................... 22 CALCIUM REGULATORS ........................................................................................................................................................................... 23 CONTRACEPTIVES .................................................................................................................................................................................... 23 ENDOMETRIOSIS ....................................................................................................................................................................................... 24 ESTROGENS ............................................................................................................................................................................................... 25 ESTROGEN/PROGESTINS ......................................................................................................................................................................... 25 FERTILITY REGULATORS .......................................................................................................................................................................... 25 GLUCOCORTICOIDS .................................................................................................................................................................................. 25 GLUCOSE ELEVATING AGENTS ............................................................................................................................................................... 25 HUMAN GROWTH HORMONES ................................................................................................................................................................. 25 HYPERPARATHYROID TREATMENT, VITAMIN D ANALOGS ................................................................................................................. 25 PHENYLKETONURIA TREATMENT AGENTS ........................................................................................................................................... 26 PHOSPHATE BINDER AGENTS ................................................................................................................................................................. 26 POTASSIUM-REMOVING AGENTS ............................................................................................................................................................ 26 PROGESTINS .............................................................................................................................................................................................. 26 SELECTIVE ESTROGEN RECEPTOR MODULATORS ............................................................................................................................. 26 THYROID AGENTS ..................................................................................................................................................................................... 26 UREA CYCLE DISORDERS ........................................................................................................................................................................ 26 VASOPRESSIN RECEPTOR ANTAGONISTS ............................................................................................................................................ 26 VASOPRESSINS ......................................................................................................................................................................................... 26 MISCELLANEOUS ....................................................................................................................................................................................... 26

GASTROINTESTINAL ........................................................................................................................................................................................... 26 ANTIDIARRHEALS ...................................................................................................................................................................................... 26 ANTIEMETICS ............................................................................................................................................................................................. 27 ANTISPASMODICS ..................................................................................................................................................................................... 27 CHOLELITHOLYTICS .................................................................................................................................................................................. 27 H2 RECEPTOR ANTAGONISTS .................................................................................................................................................................. 27 INFLAMMATORY BOWEL DISEASE .......................................................................................................................................................... 27 LAXATIVES/STOOL SOFTENERS .............................................................................................................................................................. 27 OPIOID-INDUCED CONSTIPATION ........................................................................................................................................................... 27 PANCREATIC ENZYMES ............................................................................................................................................................................ 27 PROSTAGLANDINS .................................................................................................................................................................................... 28 PROTON PUMP INHIBITORS ..................................................................................................................................................................... 28 SALIVA STIMULANTS ................................................................................................................................................................................. 28 STEROIDS, RECTAL ................................................................................................................................................................................... 28 MISCELLANEOUS ....................................................................................................................................................................................... 28

GENITOURINARY .................................................................................................................................................................................................. 28 BENIGN PROSTATIC HYPERPLASIA ........................................................................................................................................................ 28 URINARY ANTISPASMODICS .................................................................................................................................................................... 28 VAGINAL ANTI-INFECTIVES ...................................................................................................................................................................... 28 MISCELLANEOUS ....................................................................................................................................................................................... 28

HEMATOLOGIC ..................................................................................................................................................................................................... 29 ANTICOAGULANTS .................................................................................................................................................................................... 29 HEMATOPOIETIC GROWTH FACTORS .................................................................................................................................................... 29 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AGENTS ........................................................................................................ 29 PLATELET AGGREGATION INHIBITORS .................................................................................................................................................. 29 PLATELET SYNTHESIS INHIBITORS ........................................................................................................................................................ 29 THROMBOCYTOPENIA AGENTS .............................................................................................................................................................. 29

3

MISCELLANEOUS ....................................................................................................................................................................................... 29 IMMUNOLOGIC AGENTS ...................................................................................................................................................................................... 30

AUTOIMMUNE AGENTS ............................................................................................................................................................................. 30 DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs) ................................................................................................................. 30 HEREDITARY ANGIOEDEMA AGENTS ..................................................................................................................................................... 30 IMMUNOMODULATORS ............................................................................................................................................................................. 30 IMMUNOSUPPRESSANTS ......................................................................................................................................................................... 30

NUTRITIONAL/SUPPLEMENTS ............................................................................................................................................................................ 30 ELECTROLYTES ......................................................................................................................................................................................... 30 VITAMINS AND MINERALS ........................................................................................................................................................................ 31

RESPIRATORY ...................................................................................................................................................................................................... 31 ANAPHYLAXIS TREATMENT AGENTS...................................................................................................................................................... 31 ANTICHOLINERGICS .................................................................................................................................................................................. 31 ANTICHOLINERGIC/BETA AGONIST COMBINATIONS ............................................................................................................................ 31 ANTIHISTAMINES, LOW SEDATING.......................................................................................................................................................... 32 ANTIHISTAMINES, SEDATING ................................................................................................................................................................... 32 ANTIHISTAMINE/DECONGESTANT COMBINATIONS .............................................................................................................................. 32 ANTITUSSIVES............................................................................................................................................................................................ 32 ANTITUSSIVE COMBINATIONS ................................................................................................................................................................. 32 BETA AGONISTS ........................................................................................................................................................................................ 32 CYSTIC FIBROSIS ...................................................................................................................................................................................... 32 LEUKOTRIENE MODULATORS .................................................................................................................................................................. 32 MAST CELL STABILIZERS ......................................................................................................................................................................... 33 MEDICAL SUPPLIES ................................................................................................................................................................................... 33 NASAL ANTIHISTAMINES .......................................................................................................................................................................... 33 NASAL STEROIDS ...................................................................................................................................................................................... 33 PULMONARY FIBROSIS AGENTS ............................................................................................................................................................. 33 RESPIRATORY SYNCYTIAL VIRUS ........................................................................................................................................................... 33 SEVERE ASTHMA AGENTS ....................................................................................................................................................................... 33 STEROID/BETA AGONIST COMBINATIONS ............................................................................................................................................. 33 STEROID INHALANTS ................................................................................................................................................................................ 33 XANTHINES ................................................................................................................................................................................................. 33 MISCELLANEOUS ....................................................................................................................................................................................... 33

TOPICAL ................................................................................................................................................................................................................ 33 DERMATOLOGY ......................................................................................................................................................................................... 33 MOUTH/THROAT/DENTAL AGENTS ......................................................................................................................................................... 35 OPHTHALMIC .............................................................................................................................................................................................. 36 OTIC ............................................................................................................................................................................................................. 37

WEBSITES ............................................................................................................................................................................................................. 38 INDEX ..................................................................................................................................................................................................................... 40

4

INTRODUCTION We are pleased to provide the 2020 MetroPlus Health Plan Formulary as a useful reference and informational tool. This document can assist medical providers in selecting clinically appropriate and cost-effective products for their patients. The drugs represented have been reviewed by a National Pharmacy and Therapeutics (P&T) Committee and are approved for inclusion. The document is reflective of current medical practice as of the date of review. The information contained in this document and its appendices is provided solely for the convenience of medical providers. We do not warrant or assure accuracy of such information nor is it intended to be comprehensive in nature. This document is not intended to be a substitute for the knowledge, expertise, skill and judgment of the medical provider in his or her choice of prescription drugs. All the information in the document is provided as a reference for drug therapy selection. Specific drug selection for an individual patient rests solely with the prescriber. The document is subject to state-specific regulations and rules, including, but not limited to, those regarding generic substitution, controlled substance schedules, preference for brands and mandatory generics whenever applicable. We assume no responsibility for the actions or omissions of any medical provider based upon reliance, in whole or in part, on the information contained herein. The medical provider should consult the drug manufacturer's product literature or standard references for more detailed information. National guidelines can be found on the National Guideline Clearinghouse site at https://www.ahrq.gov/gam/, on the websites listed under each therapeutic class and on the sites listed in the Websites section of this publication.

PREFACE The document is organized by sections. Each section is divided by therapeutic drug class primarily defined by mechanism of action. Products are listed by generic name with brand name for reference only. Unless the cited drug is available as an injectable or an exception is specifically noted, generally, all applicable oral dosage forms and strengths of the drug cited are included in the document. Drugs represented in this document may have varying cost to the plan member based on the plan's benefit structure. Generic medications typically are available at the lower cost, brand-name medications on the document will generally cost more than generics. Generics should be considered the first line of prescribing subject to applicable rules.

DRUG LIST PRODUCT DESCRIPTIONS To assist in understanding which specific strengths and dosage forms on the document are covered, examples are noted below. The general principles shown in the examples can usually be extended to other entries in the document. Any exceptions are noted. Listed products on the document generally include all strengths and dosage forms of the cited brand-name product. pregabalin Lyrica Oral capsules, oral solution and all strengths of Lyrica would be included in this listing. When a strength or dosage form is specified, only the specified strength and dosage form is on the document. Other strengths/dosage forms, including injectable dosage forms of the reference product are not. esomeprazole magnesium delayed-rel suspension 2.5 mg, 5 mg, 10

mg Nexium suspension

The oral suspension dosage form of Nexium is on the document. From this entry, the oral capsule cannot be assumed to be on the list unless there is a separate entry. Extended-release and delayed-release products require their own entry. tofacitinib Xeljanz The immediate-release product listing of Xeljanz alone would not include the extended-release product Xeljanz XR. tofacitinib ext-rel Xeljanz XR A separate entry for Xeljanz XR confirms that the extended-release product is on the document.

5

Dosage forms on the document will be consistent with the category and use where listed. nystatin The above nystatin entry listed in the TOPICAL/DERMATOLOGY section is limited to the topical dosage forms. From this entry the oral formulations cannot be assumed to be on the list unless there is an entry for this product in the ANTI-INFECTIVES section of the document.

GENERIC SUBSTITUTION

Generic substitution is a pharmacy action whereby a generic version is dispensed rather than a prescribed brand-name product. Boldface type indicates generic availability. However, not all strengths or dosage forms of the generic name in boldface type may be generically available. In most instances, a brand-name drug for which a generic product becomes available will become non-formulary, with the generic product covered in its place, upon release of the generic product to the market. However, the document is subject to state specific regulations and rules regarding generic substitution and mandatory generic rules apply where appropriate. Generic drugs are usually priced lower than their brand-name equivalents. Prescription generic drugs are:

Approved by the U.S. Food and Drug Administration (FDA) for safety and effectiveness, and are manufactured under the same strict standards that apply to brand-name drugs.

Tested in humans to assure the generic is absorbed into the bloodstream in a similar rate and extent compared to the brand-name drug (bioequivalence). Generics may be different from the brand in size, color and inactive ingredients, but this does not alter their effectiveness or ability to be absorbed just like the brand-name drug.

Manufactured in the same strength and dosage form as the brand-name drugs.

When a generic drug is substituted for a brand-name drug, you can expect the generic to produce the same clinical effect and safety profile as the brand-name drug (therapeutic equivalence).

NON-COVERED MEDICATIONS Pharmaceuticals determined by the FDA to be less than effective and identical, related, or similar drugs

(commonly referred to as DESI 5 and 6 drugs). MetroPlus only covers drugs from manufacturers participating in the Federal Medicaid drug rebate program.

OVER-THE-COUNTER DRUG COVERAGE MetroPlus covers over-the-counter (OTC) drugs that obtain fiscal orders that meet Medicaid criteria. These include select medications in the following categories: analgesic and antipyretic, antacid, anti-diarrheal, antihistamine, anti-vertigo, artificial tears and ocular/oral lubricants, chronic renal disease, cough and cold, dermatological, family planning, fecal softener and laxative, hematinic, insulin, pediculicide, smoking cessation agents, and vitamins/minerals. All categories are represented on the formulary. However, not every item made by every manufacturer is covered. Furthermore, not all formulations and/or package sizes are covered. Quantities may also be limited based on acute/episodic vs. chronic/maintenance uses. For the most up-to-date list of covered OTC products, please reference: https://www.emedny.org/info/formfile.aspx

SPECIALTY PLAN DESIGN Specialty Guideline Management (SGM) SGM is our utilization management program that helps ensure appropriate utilization for specialty medication based on currently accepted evidence-based medicine guidelines. SGM is designed to help ensure safety and efficacy while preventing off-guideline utilization. Medications which may be included in the SGM program are identified in the document as “SGM” for your reference. Prescribers may call 1-866-814-5506 to enroll patients in Specialty plan design.

6

PLAN DESIGN The document represents a closed formulary plan design. The medications listed on the document are covered by the plan as represented. Certain medications on the list are covered if utilization management criteria are met (i.e., Step Therapy, Prior Authorization, Quantity Limits, etc.); requests for use of such medications outside of their listed criteria will be reviewed for medical necessity. If a medication is not listed on the document, a formulary exception may be requested for coverage. Medical necessity or formulary exception requests will be reviewed based on drug-specific prior authorization criteria or standard non-formulary prescription request criteria.

LEGEND

AL Age Limit OTC Over the counter PA Prior Authorization PA, QL Quantity Limit is applied after Prior Authorization approval QL Quantity Limit SGM Specialty Guideline Management ST Step Therapy boldface Indicates generic availability; boldface may not apply to every strength or dosage form under the

listed generic name delayed-rel Delayed-release (also known as enteric-coated), refer to the reference brand listed for clarification ext-rel Extended-release (also known as sustained-release), refer to the reference brand listed for

clarification

NOTICE The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission. ©2020. All rights reserved. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers. MetroPlus Health Plan does not operate the websites/organizations listed here, nor is it responsible for the availability or reliability of the websites' content. These listings do not imply or constitute an endorsement, sponsorship or recommendation by MetroPlus Health Plan. Please be advised that this document is updated periodically and changes may appear prior to their effective date to allow for client notification.

7

ANALGESICS Practice guidelines of pain management are available at: https://www.asahq.org Treatment recommendations for osteoarthritis are available at: https://www.rheumatology.org NSAIDs

diclofenac sodium delayed-rel diclofenac sodium ext-rel diflunisal etodolac etodolac ext-rel flurbiprofen ibuprofen QL ketorolac meloxicam MOBIC nabumetone naproxen NAPROSYN naproxen sodium oxaprozin DAYPRO sulindac

COX-2 INHIBITORS

PA celecoxib CELEBREX GOUT

allopurinol ZYLOPRIM QL colchicine tabs COLCRYS probenecid

OPIOID ANALGESICS Practice Guidelines for Cancer Pain Management (includes WHO analgesic ladder) are available at: https://www.asahq.org https://www.nccn.org Opioid guidelines in the management of chronic non-malignant pain are available at: https://www.asipp.org/ASIPP-Guidelines.html The quantity of opioid products covered (including those that are combined with acetaminophen, aspirin or ibuprofen) will be limited to up to 90 morphine milligram equivalents (MMEs) per day based on a 30-day supply. Members may be subject to additional quantity limit restrictions, including a first-fill limit of 7 days (for members who are opioid-naïve) and 90 days of treatment per 365 days.

QL codeine/acetaminophen PA, QL fentanyl transdermal DURAGESIC QL hydrocodone/acetaminophen NORCO PA, QL hydromorphone ext-rel QL hydromorphone tabs DILAUDID PA, QL methadone tabs 5 mg, 10 mg DOLOPHINE QL morphine PA, QL morphine ext-rel MS CONTIN QL oxycodone QL oxycodone ROXICODONE QL oxycodone/acetaminophen PERCOCET QL oxycodone/aspirin PERCODAN QL tramadol 50 mg ULTRAM PA, QL tramadol ext-rel tabs

8

QL tramadol/acetaminophen ULTRACET NON-OPIOID ANALGESICS

QL butalbital/acetaminophen/caffeine ESGIC QL butalbital/aspirin/caffeine FIORINAL

ANTI-INFECTIVES Practice guidelines and statements developed and endorsed by the Infectious Diseases Society of America are available at: https://www.idsociety.org Hepatitis: CDC recommendations on the treatment of hepatitis are available at: https://www.cdc.gov/hepatitis/Resources/ Guidelines for the management of chronic hepatitis by the American Association for the Study of Liver Disease are available at: https://www.aasld.org HIV/AIDS: Guidelines for the treatment of HIV patients by the U.S. Department of Health and Human Services are available at: https://www.aidsinfo.nih.gov Infective Endocarditis: American Heart Association recommendations for the prevention of bacterial endocarditis are available at: https://professional.heart.org Influenza: Recommendations of the Advisory Committee on Immunization Practices are available at: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html International Travel: CDC recommendations for international travel are available at: https://wwwnc.cdc.gov/travel Respiratory Tract Infection/Antibiotic Use/Community Acquired Pneumonia/Other: Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infection in adults are available at: https://www.cdc.gov/pneumonia/management-prevention-guidelines.html Sexually Transmitted Diseases: CDC Sexually Transmitted Diseases Guidelines are available at: https://www.cdc.gov/std/treatment/default.htm ANTIBACTERIALS Aminoglycosides

neomycin Cephalosporins Cephalosporin Combinations

PA ceftolozane/tazobactam ZERBAXA First Generation

cefadroxil cephalexin KEFLEX

Second Generation

cefprozil cefuroxime axetil

Third Generation

cefdinir Erythromycins/Macrolides

azithromycin ZITHROMAX clarithromycin clarithromycin ext-rel

9

erythromycin base erythromycin delayed-rel erythromycin ethylsuccinate erythromycin stearate

Fluoroquinolones

ciprofloxacin tabs CIPRO levofloxacin

Penicillins

amoxicillin amoxicillin/clavulanate AUGMENTIN ampicillin dicloxacillin penicillin G BICILLIN L-A penicillin VK

Sulfonamides

sulfadiazine sulfamethoxazole/trimethoprim sulfamethoxazole/trimethoprim DS

Tetracyclines

doxycycline monohydrate caps 50 mg, 100 mg doxycycline monohydrate suspension VIBRAMYCIN doxycycline monohydrate tabs 50 mg, 75 mg, 100 mg minocycline MINOCIN tetracycline

ANTIFUNGALS

clotrimazole troches fluconazole DIFLUCAN griseofulvin microsize suspension griseofulvin ultramicrosize PA, QL itraconazole caps SPORANOX nystatin QL terbinafine tabs PA voriconazole VFEND

ANTIMALARIALS

QL atovaquone/proguanil MALARONE QL chloroquine QL mefloquine

ANTIRETROVIRAL AGENTS Antiretroviral Adjuvants

QL cobicistat TYBOST Antiretroviral Combinations

QL abacavir/dolutegravir/lamivudine TRIUMEQ QL abacavir/lamivudine EPZICOM QL abacavir/lamivudine/zidovudine TRIZIVIR QL atazanavir/cobicistat EVOTAZ QL bictegravir/emtricitabine/tenofovir alafenamide BIKTARVY QL darunavir/cobicistat PREZCOBIX QL darunavir/cobicistat/emtricitabine/tenofovir alafenamide SYMTUZA QL dolutegravir/lamivudine DOVATO QL dolutegravir/rilpivirine JULUCA

10

QL efavirenz/emtricitabine/tenofovir disoproxil fumarate ATRIPLA QL efavirenz/lamivudine/tenofovir disoproxil fumarate SYMFI QL efavirenz/lamivudine/tenofovir disoproxil fumarate SYMFI LO QL elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide GENVOYA QL elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate STRIBILD QL emtricitabine/rilpivirine/tenofovir alafenamide ODEFSEY QL emtricitabine/rilpivirine/tenofovir disoproxil fumarate COMPLERA QL, * emtricitabine/tenofovir alafenamide DESCOVY QL, * emtricitabine/tenofovir disoproxil fumarate TRUVADA QL lamivudine/tenofovir disoproxil fumarate CIMDUO QL lamivudine/zidovudine COMBIVIR

* Documentation may be required for select instances in which product labeling dictates monitoring Chemokine Receptor Antagonists

QL maraviroc SELZENTRY Integrase Inhibitors

QL dolutegravir TIVICAY QL raltegravir ISENTRESS

Non-nucleoside Reverse Transcriptase Inhibitors

QL efavirenz SUSTIVA QL etravirine INTELENCE QL nevirapine VIRAMUNE QL nevirapine ext-rel VIRAMUNE XR QL rilpivirine EDURANT

Nucleoside Reverse Transcriptase Inhibitors

QL abacavir ZIAGEN QL didanosine delayed-rel QL emtricitabine EMTRIVA QL lamivudine EPIVIR QL stavudine QL zidovudine RETROVIR

Nucleotide Reverse Transcriptase Inhibitors

QL tenofovir disoproxil fumarate VIREAD Protease Inhibitors

QL atazanavir REYATAZ QL darunavir PREZISTA QL fosamprenavir LEXIVA QL indinavir CRIXIVAN QL lopinavir/ritonavir KALETRA QL nelfinavir VIRACEPT QL ritonavir NORVIR QL tipranavir APTIVUS

ANTITUBERCULAR AGENTS

ethambutol MYAMBUTOL isoniazid pyrazinamide rifampin RIFADIN

ANTIVIRALS Cytomegalovirus Agents

QL valganciclovir VALCYTE

11

Hepatitis Agents Hepatitis B

adefovir dipivoxil HEPSERA entecavir solution BARACLUDE entecavir tabs BARACLUDE lamivudine tabs EPIVIR-HBV

Hepatitis C

#, SGM glecaprevir/pibrentasvir MAVYRET SGM ribavirin caps, tabs 200mg SGM sofosbuvir/velpatasvir

# MAVYRET for genotypes 1, 2, 3, 4, 5, 6 Herpes Agents

acyclovir caps, suspension, tabs ZOVIRAX famciclovir valacyclovir VALTREX

Influenza Agents

QL oseltamivir TAMIFLU MISCELLANEOUS

ST atovaquone MEPRON clindamycin CLEOCIN dapsone ivermectin STROMECTOL PA linezolid ZYVOX PA linezolid injection ZYVOX QL mebendazole EMVERM metronidazole FLAGYL nitrofurantoin ext-rel MACROBID nitrofurantoin macrocrystals MACRODANTIN nitrofurantoin suspension PA pyrimethamine DARAPRIM rifabutin MYCOBUTIN trimethoprim QL vancomycin VANCOCIN

ANTINEOPLASTIC AGENTS Clinical practice guidelines in oncology are available at: https://www.asco.org https://www.nccn.org ALKYLATING AGENTS

busulfan MYLERAN chlorambucil LEUKERAN cyclophosphamide caps lomustine GLEOSTINE melphalan ALKERAN SGM temozolomide TEMODAR

ANTIMETABOLITES

SGM capecitabine XELODA mercaptopurine methotrexate TREXALL

12

HORMONAL ANTINEOPLASTIC AGENTS Antiandrogens

bicalutamide CASODEX SGM enzalutamide XTANDI flutamide

Antiestrogens

SGM fulvestrant FASLODEX tamoxifen toremifene FARESTON

Aromatase Inhibitors

anastrozole ARIMIDEX exemestane AROMASIN letrozole FEMARA

Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

SGM goserelin acetate ZOLADEX SGM leuprolide acetate SGM leuprolide acetate LUPRON DEPOT SGM triptorelin pamoate TRELSTAR

Gonadotropin Releasing Hormone (GnRH) Antagonists

SGM degarelix acetate FIRMAGON Progestins

megestrol acetate MEGACE IMMUNOMODULATORS

SGM lenalidomide REVLIMID KINASE INHIBITORS

SGM afatinib GILOTRIF SGM axitinib INLYTA SGM bosutinib BOSULIF SGM, QL cabozantinib CABOMETYX SGM cabozantinib COMETRIQ SGM ceritinib ZYKADIA SGM dabrafenib TAFINLAR SGM dasatinib SPRYCEL SGM erlotinib TARCEVA SGM everolimus AFINITOR SGM ibrutinib IMBRUVICA SGM idelalisib ZYDELIG SGM imatinib mesylate GLEEVEC SGM lapatinib TYKERB SGM lenvatinib LENVIMA SGM midostaurin RYDAPT SGM nilotinib TASIGNA SGM palbociclib IBRANCE SGM pazopanib VOTRIENT SGM ponatinib ICLUSIG SGM regorafenib STIVARGA SGM ruxolitinib JAKAFI SGM sorafenib NEXAVAR SGM sunitinib SUTENT SGM trametinib MEKINIST SGM vandetanib CAPRELSA

13

SGM vemurafenib ZELBORAF MISCELLANEOUS

SGM bexarotene caps TARGRETIN etoposide hydroxyurea HYDREA leucovorin mitotane LYSODREN SGM niraparib ZEJULA SGM olaparib LYNPARZA SGM panobinostat FARYDAK procarbazine MATULANE SGM rucaparib RUBRACA tretinoin caps QL uridine triacetate VISTOGARD SGM venetoclax VENCLEXTA SGM vismodegib ERIVEDGE SGM vorinostat ZOLINZA

CARDIOVASCULAR The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure is available at: https://jamanetwork.com/journals/jama/fullarticle/1791497 Guidelines for the evaluation and management of cardiovascular diseases in adults are available at: https://www.acc.org https://professional.heart.org ACE INHIBITORS Guidelines for the use of ACE inhibitors are available at: https://jamanetwork.com/journals/jama/fullarticle/1791497 https://professional.diabetes.org https://www.acc.org https://professional.heart.org

benazepril LOTENSIN captopril enalapril VASOTEC fosinopril lisinopril ZESTRIL quinapril ACCUPRIL ramipril ALTACE trandolapril

ACE INHIBITOR/CALCIUM CHANNEL BLOCKER COMBINATIONS

amlodipine/benazepril LOTREL ACE INHIBITOR/DIURETIC COMBINATIONS

benazepril/hydrochlorothiazide LOTENSIN HCT captopril/hydrochlorothiazide enalapril/hydrochlorothiazide VASERETIC fosinopril/hydrochlorothiazide lisinopril/hydrochlorothiazide ZESTORETIC quinapril/hydrochlorothiazide ACCURETIC

ADRENOLYTICS, CENTRAL

clonidine CATAPRES clonidine transdermal CATAPRES-TTS

14

guanfacine ALDOSTERONE RECEPTOR ANTAGONISTS

eplerenone INSPRA spironolactone ALDACTONE

ALPHA BLOCKERS Guidelines for the use of alpha blockers in various patient populations are available at: https://jamanetwork.com/journals/jama/fullarticle/1791497

doxazosin CARDURA prazosin MINIPRESS terazosin

ANGIOTENSIN II RECEPTOR ANTAGONISTS/DIURETIC COMBINATIONS Guidelines for the use of angiotensin II receptor antagonists in various patient populations are available at: https://jamanetwork.com/journals/jama/fullarticle/1791497 https://professional.diabetes.org

irbesartan AVAPRO irbesartan/hydrochlorothiazide AVALIDE losartan COZAAR losartan/hydrochlorothiazide HYZAAR valsartan DIOVAN valsartan/hydrochlorothiazide DIOVAN HCT

ANTIARRHYTHMICS Guidelines for the use of antiarrhythmics and cardiac glycosides in various patient populations are available at: https://www.acc.org

amiodarone disopyramide NORPACE disopyramide ext-rel NORPACE CR SGM dofetilide TIKOSYN flecainide propafenone propafenone ext-rel RYTHMOL SR sotalol BETAPACE sotalol BETAPACE AF

ANTILIPEMICS The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol is available at: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000625 Bile Acid Resins

cholestyramine QUESTRAN/QUESTRAN LIGHT colestipol COLESTID

Cholesterol Absorption Inhibitors

ezetimibe ZETIA Fibrates

fenofibrate fenofibrate TRICOR gemfibrozil LOPID

15

HMG-CoA Reductase Inhibitors atorvastatin LIPITOR lovastatin pravastatin PRAVACHOL ST rosuvastatin CRESTOR simvastatin ZOCOR

Niacins

niacin ext-rel NIASPAN Omega-3 Fatty Acids

PA icosapent ethyl VASCEPA PCSK9 Inhibitors

SGM evolocumab REPATHA BETA-BLOCKERS Guidelines for the use of beta-blockers and beta-blocker combinations in various patient populations are available at: https://jamanetwork.com/journals/jama/fullarticle/1791497 https://www.acc.org

atenolol TENORMIN bisoprolol carvedilol COREG labetalol metoprolol succinate ext-rel TOPROL-XL metoprolol tartrate 25 mg, 50 mg, 100 mg LOPRESSOR nadolol CORGARD pindolol propranolol propranolol ext-rel INDERAL LA timolol

BETA-BLOCKER/DIURETIC COMBINATIONS Guidelines for the use of beta-blockers and diuretic combinations in various patient populations are available at: https://jamanetwork.com/journals/jama/fullarticle/1791497 https://www.acc.org

atenolol/chlorthalidone TENORETIC bisoprolol/hydrochlorothiazide ZIAC metoprolol/hydrochlorothiazide LOPRESSOR HCT

CALCIUM CHANNEL BLOCKERS Dihydropyridines

amlodipine NORVASC felodipine ext-rel nifedipine ext-rel nifedipine ext-rel PROCARDIA XL

Nondihydropyridines

diltiazem CARDIZEM diltiazem ext-rel diltiazem ext-rel CARDIZEM CD diltiazem ext-rel TIAZAC diltiazem ext-rel, except 120 mg CARDIZEM LA verapamil ext-rel CALAN SR verapamil ext-rel VERELAN PM

16

DIGITALIS GLYCOSIDES digoxin LANOXIN digoxin pediatric elixir

DIURETICS Carbonic Anhydrase Inhibitors

acetazolamide acetazolamide ext-rel methazolamide

Loop Diuretics

bumetanide furosemide LASIX torsemide

Potassium-sparing Diuretics

amiloride Thiazides and Thiazide-like Diuretics

chlorthalidone hydrochlorothiazide indapamide metolazone

Diuretic Combinations

amiloride/hydrochlorothiazide spironolactone/hydrochlorothiazide ALDACTAZIDE triamterene/hydrochlorothiazide DYAZIDE triamterene/hydrochlorothiazide MAXZIDE

HEART FAILURE

ivabradine CORLANOR sacubitril/valsartan ENTRESTO

NITRATES Oral

isosorbide dinitrate 5 mg, 10 mg, 20 mg, 30 mg ISORDIL isosorbide mononitrate isosorbide mononitrate ext-rel nitroglycerin ext-rel

Sublingual

nitroglycerin sublingual NITROSTAT Transdermal

nitroglycerin ointment NITRO-BID nitroglycerin transdermal nitroglycerin transdermal NITRO-DUR

PULMONARY ARTERIAL HYPERTENSION Endothelin Receptor Antagonists

SGM ambrisentan LETAIRIS SGM bosentan TRACLEER

Phosphodiesterase Inhibitors

SGM sildenafil REVATIO

17

Prostaglandin Vasodilators SGM epoprostenol sodium FLOLAN SGM iloprost VENTAVIS SGM treprostinil REMODULIN SGM treprostinil TYVASO

MISCELLANEOUS

hydralazine methyldopa midodrine

CENTRAL NERVOUS SYSTEM Practice guidelines for psychiatric disorders are available at: https://www.psychiatry.org ANTIANXIETY Benzodiazepines

QL alprazolam XANAX QL chlordiazepoxide QL clonazepam tabs KLONOPIN QL diazepam VALIUM QL lorazepam ATIVAN QL oxazepam

Miscellaneous

buspirone QL* clomipramine ANAFRANIL fluvoxamine

QL* Only applies to members of age 65 and older ANTICONVULSANTS Practice guidelines for the treatment of epilepsy are available at: https://www.aan.com

carbamazepine TEGRETOL carbamazepine ext-rel CARBATROL carbamazepine ext-rel TEGRETOL-XR diazepam rectal gel DIASTAT divalproex sodium delayed-rel DEPAKOTE divalproex sodium ext-rel DEPAKOTE ER ethosuximide ZARONTIN QL gabapentin NEURONTIN lamotrigine LAMICTAL levetiracetam KEPPRA levetiracetam injection KEPPRA oxcarbazepine TRILEPTAL phenobarbital phenytoin DILANTIN INFATABS phenytoin sodium extended DILANTIN phenytoin sodium extended PHENYTEK primidone MYSOLINE tiagabine GABITRIL topiramate sprinkle caps, tabs TOPAMAX valproic acid SGM vigabatrin SABRIL zonisamide ZONEGRAN

18

ANTIDEMENTIA Practice guidelines for the management of dementia are available at: https://www.aan.com

donepezil ARICEPT galantamine RAZADYNE galantamine ext-rel RAZADYNE ER PA* memantine NAMENDA PA rivastigmine caps, solution PA rivastigmine transdermal EXELON PATCH

PA* Only applies to members < 30 years of age ANTIDEPRESSANTS Although these agents are primarily indicated for depression, some of these are also approved for other indications, including bipolar disorder, obsessive-compulsive disorder, panic disorder and premenstrual dysphoric disorder. Guidelines for the evaluation and management of bipolar and depressive disorders are available at: https://www.psychiatry.org Monoamine Oxidase Inhibitors (MAOIs)

isocarboxazid MARPLAN phenelzine NARDIL tranylcypromine PARNATE

Selective Serotonin Reuptake Inhibitors (SSRIs)

citalopram CELEXA escitalopram LEXAPRO fluoxetine caps PROZAC paroxetine HCl ext-rel PAXIL CR paroxetine HCl tabs PAXIL sertraline ZOLOFT

Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

PA duloxetine delayed-rel CYMBALTA venlafaxine venlafaxine ext-rel EFFEXOR XR

Tricyclic Antidepressants (TCAs)

QL* amitriptyline QL* desipramine NORPRAMIN QL* doxepin QL* imipramine HCl QL* nortriptyline PAMELOR

QL* Only applies to members of age 65 and older Miscellaneous Agents

bupropion bupropion ext-rel WELLBUTRIN SR bupropion ext-rel WELLBUTRIN XL mirtazapine REMERON trazodone

19

ANTIPARKINSONIAN AGENTS Practice guidelines for the diagnosis and treatment of Parkinson's disease are available at: https://www.aan.com

amantadine benztropine PA bromocriptine PARLODEL carbidopa/levodopa SINEMET carbidopa/levodopa ext-rel carbidopa/levodopa orally disintegrating tabs carbidopa/levodopa/entacapone STALEVO entacapone COMTAN pramipexole MIRAPEX ropinirole selegiline trihexyphenidyl

ANTIPSYCHOTICS Atypicals

aripiprazole ABILIFY aripiprazole ext-rel injection ABILIFY MAINTENA aripiprazole lauroxil ext-rel injection ARISTADA aripiprazole lauroxil ext-rel injection ARISTADA INITIO aripiprazole orally disintegrating tabs PA asenapine SAPHRIS clozapine CLOZARIL clozapine orally disintegrating tabs PA iloperidone FANAPT PA lurasidone LATUDA olanzapine ZYPREXA PA paliperidone ext-rel INVEGA paliperidone palmitate ext-rel injection INVEGA SUSTENNA paliperidone palmitate ext-rel injection INVEGA TRINZA quetiapine SEROQUEL PA quetiapine ext-rel SEROQUEL XR risperidone RISPERDAL risperidone long-acting injection RISPERDAL CONSTA ziprasidone GEODON

Miscellaneous

chlorpromazine fluphenazine fluphenazine decanoate injection fluphenazine injection haloperidol haloperidol decanoate injection HALDOL DECANOATE haloperidol lactate injection HALDOL perphenazine SGM pimavanserin NUPLAZID thiothixene trifluoperazine

20

ATTENTION DEFICIT HYPERACTIVITY DISORDER Guidelines for the evaluation and management of attention deficit disorder are available at: https://www.aacap.org https://www.aap.org

QL amphetamine/dextroamphetamine mixed salts ADDERALL QL amphetamine/dextroamphetamine mixed salts ext-rel ADDERALL XR ST, QL atomoxetine STRATTERA QL dexmethylphenidate FOCALIN QL dextroamphetamine ext-rel DEXEDRINE SPANSULE QL dextroamphetamine tabs 5 mg, 10 mg QL methylphenidate RITALIN QL methylphenidate ext-rel QL methylphenidate ext-rel CONCERTA ST, QL methylphenidate ext-rel 20 mg, 30 mg, 40 mg RITALIN LA QL methylphenidate ext-rel tabs 20 mg - Metadate ER QL methylphenidate solution, tabs METHYLIN

FIBROMYALGIA

PA milnacipran SAVELLA PA, QL pregabalin LYRICA

HYPNOTICS Practice parameters for the treatment of sleep disorders and clinical guidelines for the evaluation and management of chronic insomnia are available at: https://aasm.org Benzodiazepines

QL temazepam RESTORIL Nonbenzodiazepines

QL zolpidem AMBIEN MIGRAINE Guidelines for prevention and management of migraine headaches are available at: https://www.aan.com Acute Migraine Agents Triptans

ST, QL naratriptan AMERGE ST, QL rizatriptan MAXALT QL sumatriptan IMITREX QL sumatriptan injection IMITREX QL sumatriptan nasal spray IMITREX ST, QL zolmitriptan ZOMIG

MOOD STABILIZERS

lithium carbonate lithium carbonate ext-rel tabs 300 mg LITHOBID lithium carbonate ext-rel tabs 450 mg lithium citrate

MULTIPLE SCLEROSIS AGENTS Practice guidelines for multiple sclerosis are available at: https://www.aan.com

SGM dimethyl fumarate delayed-rel TECFIDERA SGM fingolimod GILENYA

21

SGM glatiramer COPAXONE SGM interferon beta-1a REBIF SGM interferon beta-1b EXTAVIA SGM teriflunomide AUBAGIO

MUSCULOSKELETAL THERAPY AGENTS

baclofen 10 mg, 20 mg QL carisoprodol SOMA chlorzoxazone 500 mg cyclobenzaprine 5 mg, 10 mg dantrolene DANTRIUM methocarbamol ROBAXIN orphenadrine ext-rel tizanidine tabs ZANAFLEX

MYASTHENIA GRAVIS

pyridostigmine MESTINON pyridostigmine ext-rel MESTINON TIMESPAN

NARCOLEPSY

PA armodafinil NUVIGIL PSYCHOTHERAPEUTIC-MISCELLANEOUS Alcohol Deterrents

acamprosate calcium disulfiram ANTABUSE naltrexone microspheres VIVITROL

Opioid Antagonists

naloxone injection QL naloxone nasal spray NARCAN naltrexone

Partial Opioid Agonists

buprenorphine sublingual Partial Opioid Agonist/Opioid Antagonist Combinations

QL buprenorphine/naloxone sublingual Pseudobulbar Affect

PA dextromethorphan/quinidine NUEDEXTA Smoking Deterrents Treating Tobacco Use and Dependence: 2008 Update-Clinical Practice Guideline is available at: https://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/index.html

bupropion ext-rel nicotine inhaler NICOTROL nicotine nasal spray NICOTROL NS varenicline CHANTIX

ENDOCRINE AND METABOLIC ANDROGENS Clinical practice guidelines for the treatment of hypogonadism are available at: https://www.aace.com

PA testosterone cypionate DEPO-TESTOSTERONE PA testosterone enanthate DELATESTRYL

22

PA testosterone gel FORTESTA PA testosterone gel 25 mg/2.5 g ANDROGEL

ANTIDIABETICS Guidelines of treatment and management of diabetes are available at: https://professional.diabetes.org Alpha-glucosidase Inhibitors

acarbose PRECOSE Biguanides

metformin metformin ext-rel

Biguanide/Sulfonylurea Combinations

glipizide/metformin METAGLIP Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

ST alogliptin Dipeptidyl Peptidase-4 (DPP-4) Inhibitor/Biguanide Combinations

ST alogliptin/metformin Incretin Mimetic Agents

ST dulaglutide TRULICITY ST liraglutide VICTOZA ST semaglutide OZEMPIC

Insulins

insulin human HUMULIN R insulin human NOVOLIN R insulin isophane human HUMULIN N insulin isophane human NOVOLIN N insulin isophane human 70%/regular 30% HUMULIN 70/30 insulin isophane human 70%/regular 30% NOVOLIN 70/30 insulin aspart protamine 70%/insulin aspart 30% NOVOLOG MIX 70/30 insulin glargine BASAGLAR insulin glargine SEMGLEE insulin lispro ADMELOG insulin lispro protamine/insulin lispro HUMALOG MIX

Insulin Sensitizers

pioglitazone ACTOS Insulin Sensitizer/Biguanide Combinations

pioglitazone/metformin ACTOPLUS MET Insulin Sensitizer/Sulfonylurea Combinations

pioglitazone/glimepiride DUETACT Meglitinides

nateglinide STARLIX repaglinide

23

Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors PA* empagliflozin JARDIANCE ST ertugliflozin STEGLATRO

PA* Covered for cardiovascular indication Sulfonylureas

glimepiride AMARYL glipizide GLUCOTROL glipizide ext-rel GLUCOTROL XL

Supplies

OTC, QL alcohol swabs OTC blood glucose monitoring kits, test strips FREESTYLE FREEDOM LITE kits and

test strips OTC blood glucose monitoring kits, test strips FREESTYLE INSULINX kits and test

strips OTC blood glucose monitoring kits, test strips FREESTYLE LITE kits and test strips OTC blood glucose monitoring kits, test strips PRECISION XTRA kits and test strips OTC insulin syringes, needles BD ULTRAFINE insulin syringes and

needles OTC lancets OTC, QL multiple urine test products KETO-DIASTIX OTC, QL multiple urine test products MULTISTIX

CALCIUM REGULATORS Guidelines of treatment and management of osteoporosis are available at: https://www.aace.com https://www.nof.org Bisphosphonates

alendronate tabs FOSAMAX Calcitonins

calcitonin-salmon MIACALCIN CONTRACEPTIVES EE = ethinyl estradiol In accordance with the Comprehensive Contraception Coverage Act (CCCA), contraceptives may be dispensed as a 12-month supply at one time. Monophasic † † Products in this category may be dispensed as a 12-month supply at one time. 20 mcg Estrogen

drospirenone/EE 3/20 YAZ levonorgestrel/EE 0.1/20 norethindrone acetate/EE 1/20 LOESTRIN 1/20 norethindrone acetate/EE 1/20 and iron LOESTRIN FE 1/20

30 mcg Estrogen

desogestrel/EE 0.15/30 - Apri drospirenone/EE 3/30 YASMIN levonorgestrel/EE 0.15/30 norethindrone acetate/EE 1.5/30 LOESTRIN 1.5/30 norethindrone acetate/EE 1.5/30 and iron LOESTRIN FE 1.5/30 norgestrel/EE 0.3/30

24

35 mcg Estrogen ethynodiol diacetate/EE 1/35 norethindrone/EE 0.4/35 norethindrone/EE 0.5/35 norethindrone/EE 1/35 norgestimate/EE 0.25/35

50 mcg Estrogen

ethynodiol diacetate/EE 1/50 Biphasic † † Products in this category may be dispensed as a 12-month supply at one time.

desogestrel/EE MIRCETTE Triphasic † † Products in this category may be dispensed as a 12-month supply at one time.

desogestrel/EE levonorgestrel/EE norethindrone/EE norgestimate/EE

Progestin Only † † Products in this category may be dispensed as a 12-month supply at one time.

norethindrone ORTHO MICRONOR Emergency Contraception

QL ulipristal ELLA Injectable † † Products in this category may be dispensed as a 12-month supply at one time.

QL medroxyprogesterone acetate 104 mg/0.65 mL DEPO-SUBQ PROVERA 104 QL medroxyprogesterone acetate 150 mg/mL DEPO-PROVERA

Transdermal † † Products in this category may be dispensed as a 12-month supply at one time.

norelgestromin/EE Vaginal † † Products in this category may be dispensed as a 12-month supply at one time.

etonogestrel/EE ring NUVARING Miscellaneous

QL diaphragm ENDOMETRIOSIS

danazol nafarelin SYNAREL

25

ESTROGENS Guidelines of treatment and management of hormone therapy and menopause are available at: https://www.menopause.org https://www.aace.com/files/menopause.pdf Oral

estradiol ESTRACE Transdermal

estradiol CLIMARA Vaginal

estradiol vaginal tabs VAGIFEM estrogens, conjugated cream PREMARIN

ESTROGEN/PROGESTINS Oral

EE/norethindrone acetate FEMHRT EE/norethindrone acetate - Jinteli estradiol/norethindrone acetate ACTIVELLA

Transdermal

estradiol/norethindrone acetate COMBIPATCH FERTILITY REGULATORS Ovulation Stimulants, Synthetic

PA, QL clomiphene GLUCOCORTICOIDS

dexamethasone fludrocortisone hydrocortisone CORTEF methylprednisolone MEDROL methylprednisolone 2 mg MEDROL methylprednisolone injection SOLU-MEDROL prednisolone sodium phosphate orally disintegrating tabs ORAPRED ODT prednisolone sodium phosphate solution 5 mg/5 mL, 15 mg/5

mL, 25 mg/5 mL

prednisolone syrup PRELONE prednisone

GLUCOSE ELEVATING AGENTS

QL glucagon, human recombinant GLUCAGEN HYPOKIT QL glucagon, human recombinant GLUCAGON EMERGENCY KIT

HUMAN GROWTH HORMONES Guidelines for use of growth hormone are available at: https://www.aace.com/publications/guidelines

SGM somatropin NORDITROPIN SGM somatropin SEROSTIM SGM somatropin ZORBTIVE

HYPERPARATHYROID TREATMENT, VITAMIN D ANALOGS

calcitriol (1,25-D3) ROCALTROL doxercalciferol HECTOROL paricalcitol ZEMPLAR

26

PHENYLKETONURIA TREATMENT AGENTS SGM sapropterin KUVAN

PHOSPHATE BINDER AGENTS

calcium acetate sevelamer carbonate tabs ST sucroferric oxyhydroxide VELPHORO

POTASSIUM-REMOVING AGENTS

sodium polystyrene sulfonate PROGESTINS Injectable

SGM hydroxyprogesterone caproate MAKENA Oral

medroxyprogesterone acetate PROVERA norethindrone acetate AYGESTIN progesterone, micronized PROMETRIUM

SELECTIVE ESTROGEN RECEPTOR MODULATORS

raloxifene EVISTA THYROID AGENTS Antithyroid Agents

methimazole TAPAZOLE propylthiouracil

Thyroid Supplements

levothyroxine levothyroxine SYNTHROID levothyroxine - Levoxyl liothyronine CYTOMEL

UREA CYCLE DISORDERS

SGM sodium phenylbutyrate BUPHENYL VASOPRESSIN RECEPTOR ANTAGONISTS

SGM tolvaptan SAMSCA VASOPRESSINS

PA desmopressin spray PA desmopressin spray, tabs DDAVP

MISCELLANEOUS

cabergoline SGM cysteamine CYSTAGON

GASTROINTESTINAL Guidelines for the treatment and management of various gastrointestinal diseases/conditions are available at: https://gi.org https://www.gastro.org ANTIDIARRHEALS

diphenoxylate/atropine LOMOTIL loperamide

27

ANTIEMETICS PA, QL aprepitant caps EMEND QL dronabinol QL granisetron tabs meclizine metoclopramide REGLAN QL ondansetron ZOFRAN prochlorperazine promethazine promethazine suppository trimethobenzamide TIGAN

ANTISPASMODICS

chlordiazepoxide/clidinium dicyclomine glycopyrrolate tabs 1 mg, 2 mg hyoscyamine sulfate LEVSIN hyoscyamine sulfate ext-rel LEVBID hyoscyamine sulfate ext-rel caps hyoscyamine sulfate orally disintegrating tabs

CHOLELITHOLYTICS

ursodiol ACTIGALL ursodiol URSO

H2 RECEPTOR ANTAGONISTS

cimetidine famotidine PEPCID nizatidine

INFLAMMATORY BOWEL DISEASE Oral Agents

balsalazide budesonide delayed-rel caps ENTOCORT EC mesalamine ext-rel caps APRISO sulfasalazine AZULFIDINE sulfasalazine delayed-rel AZULFIDINE EN-TABS

Rectal Agents

hydrocortisone enema mesalamine rectal suspension ROWASA mesalamine suppository CANASA

LAXATIVES/STOOL SOFTENERS

lactulose solution peg 3350/electrolytes peg 3350/electrolytes GOLYTELY peg 3350/electrolytes NULYTELY

OPIOID-INDUCED CONSTIPATION

naloxegol MOVANTIK PANCREATIC ENZYMES

PA pancrelipase VIOKACE PA pancrelipase delayed-rel CREON PA pancrelipase delayed-rel ZENPEP

28

PROSTAGLANDINS misoprostol CYTOTEC

PROTON PUMP INHIBITORS

AL*, QL esomeprazole magnesium delayed-rel suspension 2.5 mg, 5 mg, 10 mg

NEXIUM

QL omeprazole delayed-rel caps PRILOSEC QL pantoprazole delayed-rel tabs PROTONIX

AL* Covered for < 1 year only SALIVA STIMULANTS

pilocarpine tabs SALAGEN STEROIDS, RECTAL

hydrocortisone cream ANUSOL-HC 2.5% hydrocortisone cream PROCTOCORT 1%

MISCELLANEOUS

PA* glycopyrrolate CUVPOSA sucralfate tabs

PA* Covered for 3-16 years of age GENITOURINARY BENIGN PROSTATIC HYPERPLASIA Guidelines for the management of BPH are available at: https://www.auanet.org/guidelines

alfuzosin ext-rel UROXATRAL doxazosin CARDURA finasteride PROSCAR tamsulosin FLOMAX terazosin

URINARY ANTISPASMODICS

oxybutynin oxybutynin ext-rel DITROPAN XL trospium

* Gender restriction - Coverage for females VAGINAL ANTI-INFECTIVES

clindamycin cream CLEOCIN clotrimazole metronidazole miconazole terconazole

MISCELLANEOUS

bethanechol pentosan polysulfate sodium ELMIRON phenazopyridine PYRIDIUM potassium citrate ext-rel UROCIT-K

29

HEMATOLOGIC Guidelines of treatment and management of hemophilia are available at: https://www.hemophilia.org ANTICOAGULANTS CHEST guidelines are available at: https://www.chestnet.org/Guidelines-and-Resources/CHEST-Guideline-Topic-Areas/Pulmonary-Vascular Injectable

enoxaparin LOVENOX Oral

apixaban ELIQUIS rivaroxaban XARELTO * warfarin COUMADIN

* Both Coumadin and warfarin are covered. Synthetic Heparinoid-like Agents

fondaparinux ARIXTRA HEMATOPOIETIC GROWTH FACTORS Guidelines for the management of neutropenia are available at: https://www.asco.org Guidelines for the management of anemia associated with chronic kidney disease are available at: https://www.kidney.org/professionals/guidelines#guidelines

SGM darbepoetin alfa ARANESP SGM filgrastim-sndz ZARXIO SGM pegfilgrastim-cbqv UDENYCA

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AGENTS

SGM eculizumab SOLIRIS PLATELET AGGREGATION INHIBITORS

clopidogrel PLAVIX dipyridamole prasugrel EFFIENT ticagrelor BRILINTA

PLATELET SYNTHESIS INHIBITORS

anagrelide AGRYLIN THROMBOCYTOPENIA AGENTS

SGM eltrombopag tabs PROMACTA MISCELLANEOUS

cilostazol SGM deferasirox EXJADE SGM deferasirox JADENU

30

IMMUNOLOGIC AGENTS Guidelines for the management of rheumatic diseases are available at: https://www.rheumatology.org AUTOIMMUNE AGENTS

SGM adalimumab HUMIRA SGM brodalumab SILIQ SGM etanercept ENBREL SGM sarilumab KEVZARA SGM, QL secukinumab COSENTYX SGM tofacitinib XELJANZ SGM tofacitinib ext-rel XELJANZ XR

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDs)

hydroxychloroquine PLAQUENIL leflunomide ARAVA methotrexate SGM methotrexate injection RASUVO

HEREDITARY ANGIOEDEMA AGENTS

SGM C1 esterase inhibitor CINRYZE SGM C1 esterase inhibitor, recombinant RUCONEST

IMMUNOMODULATORS CDC recommendations on the treatment of hepatitis are available at: https://www.cdc.gov/hepatitis/Resources/ Guidelines for the management of hepatitis are available at: https://www.aasld.org Interferons

SGM interferon alfa-2b INTRON A SGM peginterferon alfa-2a PEGASYS

Miscellaneous

SGM canakinumab ILARIS IMMUNOSUPPRESSANTS Antimetabolites

azathioprine AZASAN azathioprine IMURAN mycophenolate mofetil CELLCEPT

Calcineurin Inhibitors

cyclosporine SANDIMMUNE cyclosporine, modified NEORAL tacrolimus PROGRAF

Rapamycin Derivatives

sirolimus RAPAMUNE NUTRITIONAL/SUPPLEMENTS ELECTROLYTES Potassium

potassium bicarbonate effervescent tabs 25 mEq potassium chloride ext-rel potassium chloride ext-rel K-TAB

31

potassium chloride liquid Miscellaneous

potassium phosphate K-PHOS VITAMINS AND MINERALS Folic Acid/Combinations

folic acid folic acid/vitamin B6/vitamin B12

Prenatal Vitamins

prenatal vitamins/carbonyl iron/docusate/folic acid - Prenatal AD

prenatal vitamins/carbonyl iron/ferrous fumarate/folic acid + DHA CITRANATAL MEDLEY prenatal vitamins/carbonyl iron/folic acid - Prenatabs Rx prenatal vitamins/DHA/docusate/folic acid CITRANATAL 90 DHA prenatal vitamins/DHA/docusate/folic acid CITRANATAL DHA prenatal vitamins/DHA/docusate/folic acid CITRANATAL HARMONY prenatal vitamins/docusate/folic acid CITRANATAL RX prenatal vitamins/docusate/folic acid + DHA CITRANATAL ASSURE prenatal vitamins/ferrous fumarate/docusate/folic acid -

Prenatal 19

prenatal vitamins/folic acid + pyridoxine CITRANATAL B-CALM Miscellaneous

cyanocobalamin injection ergocalciferol (D2) VITAMIN D fluoride drops, tabs multivitamins/fluoride drops, tabs multivitamins/fluoride/iron drops, tabs phytonadione MEPHYTON vitamin ADC/fluoride drops vitamin ADC/fluoride/iron drops vitamin B complex/vitamin C/folic acid NEPHROCAPS

RESPIRATORY Guidelines to the management, prevention, or treatment of COPD and asthma are available at: https://www.aaaai.org https://ginasthma.org https://goldcopd.org https://www.nhlbi.nih.gov The Allergy Report and guidelines for allergy-related conditions are available at: https://www.aaaai.org ANAPHYLAXIS TREATMENT AGENTS

QL epinephrine EPIPEN QL epinephrine EPIPEN JR. QL epinephrine auto-injector

ANTICHOLINERGICS

QL ipratropium inhalation solution QL tiotropium SPIRIVA RESPIMAT QL umeclidinium INCRUSE ELLIPTA

ANTICHOLINERGIC/BETA AGONIST COMBINATIONS Short Acting

QL ipratropium/albuterol inhalation solution

32

ANTIHISTAMINES, LOW SEDATING cetirizine

ANTIHISTAMINES, SEDATING

clemastine cyproheptadine diphenhydramine hydroxyzine HCl hydroxyzine pamoate VISTARIL

ANTIHISTAMINE/DECONGESTANT COMBINATIONS

promethazine/phenylephrine ANTITUSSIVES Clinical practice guidelines are available at: https://journal.chestnet.org/article/S0012-3692(15)52856-0/pdf

benzonatate TESSALON ANTITUSSIVE COMBINATIONS Opioid

codeine/chlorpheniramine/pseudoephedrine codeine/guaifenesin liquid codeine/guaifenesin/pseudoephedrine codeine/promethazine codeine/promethazine/phenylephrine hydrocodone/homatropine

Non-opioid

dextromethorphan/brompheniramine/pseudoephedrine dextromethorphan/promethazine

BETA AGONISTS Inhalants Short Acting

QL albuterol inhalation solution QL albuterol sulfate, CFC-free aerosol

Long Acting Hand-held Active Inhalation

QL olodaterol, CFC-free aerosol STRIVERDI RESPIMAT Oral Agents

albuterol albuterol ext-rel terbutaline

CYSTIC FIBROSIS

SGM dornase alfa PULMOZYME SGM elexacaftor/tezacaftor/ivacaftor + ivacaftor TRIKAFTA SGM ivacaftor KALYDECO SGM lumacaftor/ivacaftor ORKAMBI SGM tobramycin inhalation solution KITABIS PAK SGM tobramycin inhalation solution TOBI

LEUKOTRIENE MODULATORS

montelukast SINGULAIR

33

MAST CELL STABILIZERS QL cromolyn inhalation solution

MEDICAL SUPPLIES

OTC, QL mask OTC, QL nebulizer OTC sodium chloride inhalation solution OTC, QL spacer AEROCHAMBER OTC, QL vaporizer sodium chloride inhalation solution

NASAL ANTIHISTAMINES

QL azelastine spray NASAL STEROIDS

QL flunisolide spray PULMONARY FIBROSIS AGENTS

SGM, QL pirfenidone ESBRIET RESPIRATORY SYNCYTIAL VIRUS

SGM palivizumab SYNAGIS SEVERE ASTHMA AGENTS

SGM omalizumab XOLAIR STEROID/BETA AGONIST COMBINATIONS

QL budesonide/formoterol SYMBICORT AL*, QL fluticasone/salmeterol 100/50 ADVAIR DISKUS ST, QL mometasone/formoterol DULERA

AL* Covered for ages 4-11 years only STEROID INHALANTS

QL budesonide inhalation suspension PULMICORT RESPULES QL fluticasone FLOVENT DISKUS QL fluticasone, CFC-free aerosol FLOVENT HFA QL mometasone ASMANEX QL mometasone, CFC-free aerosol ASMANEX HFA

XANTHINES

theophylline ext-rel caps THEO-24 theophylline ext-rel tabs theophylline liquid theophylline liquid ELIXOPHYLLIN

MISCELLANEOUS

ipratropium nasal spray TOPICAL DERMATOLOGY Acne Guidelines for the care and treatment of acne vulgaris are available at: https://www.aad.org/practicecenter/quality/clinical-guidelines Oral

PA isotretinoin PA isotretinoin - Amnesteem

34

PA isotretinoin - Claravis PA isotretinoin - Myorisan PA isotretinoin - Zenatane

Topical

benzoyl peroxide, except foam QL clindamycin gel, lotion, solution CLEOCIN T QL erythromycin gel 2% QL erythromycin solution sulfacetamide lotion 10% KLARON PA tretinoin RETIN-A

Actinic Keratosis

fluorouracil cream 4% TOLAK fluorouracil cream 5% EFUDEX

Antibiotics

gentamicin mupirocin ointment silver sulfadiazine SILVADENE

Antifungals

QL ciclopirox LOPROX QL clotrimazole QL ketoconazole cream 2% QL nystatin

Antipsoriatics Guidelines of care for the management and treatment of psoriasis with topical therapies are available at: https://www.aad.org Topical

ST, QL calcipotriene ointment, solution 0.005% Antiseborrheics

ketoconazole shampoo 2% selenium sulfide lotion 2.5%

Atopic Dermatitis Guidelines for the treatment of atopic dermatitis are available at: https://www.aad.org/practicecenter/quality/clinical-guidelines

ST* tacrolimus PROTOPIC ST* tacrolimus 0.1%: In addition to clinical criteria, the member must be at least 16 years of age. Corticosteroids Low Potency

alclometasone cream, ointment 0.05% fluocinolone acetonide solution 0.01% QL hydrocortisone cream, lotion, ointment 2.5%

Medium Potency

QL betamethasone valerate cream, lotion, ointment 0.1% fluocinolone acetonide cream, ointment 0.025% QL fluticasone propionate cream 0.05%, ointment 0.005% CUTIVATE hydrocortisone butyrate solution 0.1% QL mometasone cream, lotion, ointment 0.1%

35

QL triamcinolone acetonide cream, lotion, ointment 0.025% QL triamcinolone acetonide cream, lotion, ointment 0.1%

High Potency

QL betamethasone dipropionate augmented cream 0.05% DIPROLENE AF QL betamethasone dipropionate cream, lotion, ointment 0.05% desoximetasone cream 0.25% TOPICORT QL fluocinonide cream, gel, ointment 0.05% fluocinonide solution 0.05% QL triamcinolone acetonide cream, ointment 0.5%

Very High Potency

QL betamethasone dipropionate augmented ointment 0.05% DIPROLENE clobetasol propionate solution 0.05% QL halobetasol propionate cream, ointment 0.05%

Emollients

ammonium lactate 12% Local Analgesics

PA lidocaine patch LIDODERM Local Anesthetics

QL lidocaine/prilocaine cream lidocaine/prilocaine kit

Rosacea

metronidazole cream 0.75% METROCREAM metronidazole gel 0.75% ST metronidazole gel 1% METROGEL metronidazole lotion 0.75% METROLOTION

Scabicides and Pediculicides

ST malathion OVIDE permethrin ST spinosad NATROBA

Miscellaneous Skin and Mucous Membrane

imiquimod ALDARA podofilox solution

MOUTH/THROAT/DENTAL AGENTS Anesthetics - Topical Oral

lidocaine viscous Steroids - Mouth/Throat

triamcinolone paste Miscellaneous

chlorhexidine PERIDEX AL sodium fluoride PREVIDENT

AL Covered to maximum patient age of 21

36

OPHTHALMIC Preferred Practice Pattern Guidelines for the treatment of various ophthalmic conditions are available at: https://one.aao.org Antiallergics

cromolyn sodium Antifungals

natamycin NATACYN Anti-infectives

bacitracin ciprofloxacin solution CILOXAN erythromycin gentamicin levofloxacin moxifloxacin VIGAMOX neomycin/polymyxin B/gramicidin ofloxacin OCUFLOX polymyxin B/bacitracin polymyxin B/trimethoprim POLYTRIM sulfacetamide solution 10% BLEPH-10 tobramycin solution TOBREX

Anti-infective/Anti-inflammatory Combinations

neomycin/polymyxin B/bacitracin/hydrocortisone ointment neomycin/polymyxin B/dexamethasone MAXITROL neomycin/polymyxin B/hydrocortisone suspension sulfacetamide/prednisolone phosphate 10%/0.25% tobramycin/dexamethasone suspension 0.3%/0.1% TOBRADEX

Anti-inflammatories Nonsteroidal

diclofenac sodium ketorolac 0.4% ACULAR LS ketorolac 0.5% ACULAR

Steroidal

dexamethasone sodium phosphate fluorometholone 0.1% suspension FML LIQUIFILM prednisolone acetate 1% PRED FORTE prednisolone phosphate 1%

Antivirals

trifluridine Beta-blockers Nonselective

levobunolol timolol hemihydrate BETIMOL timolol maleate TIMOPTIC timolol maleate gel TIMOPTIC-XE

Selective

betaxolol 0.5%

37

Carbonic Anhydrase Inhibitors Topical

dorzolamide TRUSOPT Carbonic Anhydrase Inhibitor/Beta-blocker Combinations

dorzolamide/timolol maleate COSOPT Carbonic Anhydrase Inhibitor/Sympathomimetic Combinations

brinzolamide/brimonidine SIMBRINZA Prostaglandins

latanoprost XALATAN Sympathomimetics

brimonidine 0.15% ALPHAGAN P brimonidine 0.2%

OTIC Clinical practice guidelines for the treatment of otitis media are available at: https://www.aap.org Anti-infectives

acetic acid ofloxacin otic

Anti-infective/Anti-inflammatory Combinations

ciprofloxacin/dexamethasone CIPRODEX neomycin/polymyxin B/hydrocortisone

38

WEBSITES Agency for Healthcare Research and Quality https://www.ahrq.gov Alzheimer's Association https://www.alz.org American Academy of Allergy, Asthma and Immunology https://www.aaaai.org American Academy of Child & Adolescent Psychiatry https://www.aacap.org American Academy of Dermatology https://www.aad.org American Academy of Neurology https://www.aan.com American Academy of Ophthalmology https://www.aao.org American Academy of Pediatrics https://www.aap.org American Association for the Study of Liver Disease https://www.aasld.org American Association of Clinical Endocrinologists https://www.aace.com American Association of Diabetes Educators https://www.diabeteseducator.org American Cancer Society https://www.cancer.org American College of Allergy, Asthma and Immunology https://www.acaai.org American College of Cardiology https://www.acc.org American College of Chest Physicians https://www.chestnet.org American College of Gastroenterology https://gi.org American College of Physicians https://www.acponline.org American College of Rheumatology https://www.rheumatology.org

American Congress of Obstetricians and Gynecologists https://www.acog.org American Diabetes Association http://www.diabetes.org American Gastroenterological Association https://www.gastro.org American Headache Society Committee for Headache Education https://americanheadachesociety.org American Heart Association https://professional.heart.org American Lung Association https://www.lung.org American Medical Association https://www.ama-assn.org American Psychiatric Association https://www.psychiatry.org American Society of Anesthesiologists https://www.asahq.org American Society of Clinical Oncology https://www.asco.org American Society of Interventional Pain Physicians https://www.asipp.org American Urological Association https://www.auanet.org Centers for Disease Control and Prevention https://www.cdc.gov Centers for Disease Control and Prevention Guideline topics: AIDS https://www.cdc.gov/hiv/default.html Centers for Disease Control and Prevention Guideline topics: Sexually Transmitted Diseases https://www.cdc.gov/std/treatment/default.htm CVS Caremark https://www.caremark.com The Food and Drug Administration https://www.fda.gov

39

Global Initiative for Asthma https://ginasthma.org Infectious Diseases Society of America https://www.idsociety.org Institute for Safe Medication Practices https://www.ismp.org Johns Hopkins AIDS Service https://www.thebody.com/content/art12096.html Juvenile Diabetes Research Foundation International https://www.jdrf.org MedWatch https://www

Documents

Medicaid Formulary | January 2021 · 2021. 1. 6. · 5 Dosage forms on the document will be consistent with the category and use where listed. nystatin The above nystatin entry listed